ELAN·Elanco Animal Health Incorporated
ELAN|Analyst Targets
ELAN|Insider Trading
ELAN|Fundamentals
ELAN|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.21 | - | - |
| Q3'25 | $0.13 | $0.19 | +43.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.2B | - | - |
| Q3'25 | - | $1.1B | - |
ELAN|Monthly Returns
Market Data
ELAN Stock Snapshot
- Market cap
- 11.19B
- Day range
- $22.16 – $22.62
- News sentiment
- 53/100 · Neutral
- Analyst target
- $31.00 (+39.2%)
- Consensus
- Buy · 25 analysts
ELAN's technical picture is under pressure, with momentum working against price. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.
Reverse DCF
What growth is priced into ELAN?
At today's price, Elanco Animal Health Incorporated needs to grow free cash flow about 36.6% a year for the next 10 years to justify its valuation at a 10.02% cost of capital. Over its actual history it has compounded free cash flow at 18.4% a year, so the market is asking for 18.2 percentage points above its own delivered rate. On that basis ELAN looks priced above what its own growth record supports.
- Implied FCF growth
- 36.6%
- Historical FCF CAGR
- 18.4%
- Growth gap
- +18.2 pts
- Verdict
- RICH
- Discount rate (WACC)
- 10.02%
- Beta
- 1.18
Behaviour On Record
What ELAN's own history says about today's numbers
- Realized volatility (21d)
- 26.2% 12th pct
- Below its peak
- -38.7%
- vs 200-day average
- -5.5%
- Up days (1y)
- 52%
Elanco Animal Health Incorporated is currently running 26.2% annualised volatility over the last 21 sessions. Measured against ELAN's own 8 years of daily returns rather than a market-wide average, that is the 12th percentile — unusually subdued by its own history, against a typical reading of 39.8%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
ELAN is trading -38.7% below its running peak. Across 7 full years on file, its median worst-drawdown-in-a-year was -36.9%, and the deepest was -60.6% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits -5.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 44th percentile — close to the gap it normally carries. Over the past year ELAN closed higher on 52% of sessions, and it is currently 2 sessions into a rising streak.
On October specifically: over 8 years of records, ELAN finished the month higher 5 of 8 times, with a median return of +2.9% and an average of -1.6%. Its strongest month historically has been May at +8.8% on average, its weakest March at -8.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: ELAN has opened more than 2% away from the prior close in 246 of 2,019 sessions (12.2% of the time), with the largest gaps running +10.9% and -12.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 2,020 daily closes between 2018-09-20 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against ELAN's own 8-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of ELAN's sector?
Elanco Animal Health Incorporated sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, ELAN ranks 10th of 15 tracked industries, lagging.
- Sector rank
- #3 of 12
- Sector state
- Lagging
- Sector rotation score
- 64
- Industry rank
- #10 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on ELAN?
UBS most recently reiterated its rating on Elanco Animal Health Incorporated to Buy on Aug 6, 2026 with a price target of $33 (from $31). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- UBS — Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Held by These ETFs
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Citadel Advisors LLC | • Hold | 9,820,211 | 1.95% | $241.68M | 2026-09-02 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Valerie Hoyle | House | OR04 | ▼ Sell | $1K - $15K | 2025-09-23 | 2025-10-10 |
| Dan Sullivan | Senate | AK | ▼ Sell | $1K - $15K | 2022-11-30 | 2023-07-26 |